Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 25;2021:8819231. doi: 10.1155/2021/8819231

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Yun Xue et al.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Resveratrol suppressed NLRP3/caspase-1/IL-1β expression and secretion in ox-LDL-treated platelets. (a) Resveratrol inhibited NLRP3, caspase-1, and IL-1β expression that was induced by ox-LDL. (b) Immunofluorescent analysis of caspase-1 expression. Resveratrol (100 μM) decreased caspase-1 expression. (c) Resveratrol (100 μM) reversed the increase in IL-1β secretion in ox-LDL-activated platelets. (d) The NLRP3 inhibitor MCC950 inhibited MMP3 and MMP9 expression that was induced by ox-LDL. (e) MCC950 (100 nM) decreased MMP3 secretion in ox-LDL-activated platelets. (f) MCC950 (100 nM) decreased MMP9 secretion in ox-LDL-activated platelets. (g) The combination of resveratrol (10 μM) and MCC950 (10 nM) synergistically inhibited the expression of caspase-1, IL-1β, MMP3, and MMP9 that was induced by ox-LDL. The data represent three independent experiments. ^#p < 0.05, ^##p < 0.01, significant difference between non-ox-LDL-treated platelets and ox-LDL-treated platelets; ^∗p < 0.05, ^∗∗p < 0.01, significant difference between MCC950- or MCC950+resveratrol-treated platelets and ox-LDL-activated platelets.